ClinicalTrials.Veeva

Menu
S

Sleep Therapy and Research Center | Medical Center Drive Office

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TAK-861
Atomoxetine
ADX-N05
E2086
Aroxybutynin
Armodafinil

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 15 total trials

A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions

The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested dose...

Enrolling
Narcolepsy Type 1
Drug: TAK-861

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

Trial sponsors

Takeda logo
Philips logo
V
A
Apnimed logo
C
D
Eisai logo
I
Jazz Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems